PDS Biotechnology Corp (PDSB) Unusual Options Activity Today

Checking PDSB unusual options activity helps you spot when traders are making outsized bets on PDS Biotechnology Corp before the broader market catches on. PDS Biotechnology Corp's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor PDSB unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching PDSB unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking PDSB unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and PDSB unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.

In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Catalysts rarely arrive without a footprint, and PDSB unusual options activity is often where that footprint shows up first. Our scanner tracks PDS Biotechnology Corp's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at PDSB unusual options volume on the call side or chasing put sweeps, PDS Biotechnology Corp's unusual options flow today is one click away, so put it on your radar before the headlines hit.